BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• Pharm Country

  Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.

  Ocean Biomedical, Inc. will host a live Research & Development update with scientific co-founders, Dr. Jack A. Elias and Dr. Jonathan Kurtis today at 2:00 pm ET on their YouTube channel.

  September 14, 2023

   · 

  5 min read
• Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase - September 14, 2023

  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Gilmartin Group Emerging Growth Company Showcase on Thursday, September 21 , 2023.

  September 14, 2023

   · 

  1 min read
• BioForest

  AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months

  The CDMO expands its AGCellerate Program to provide Lentiviral vector support for advanced therapies developers

  September 14, 2023

   · 

  2 min read
• Drug Development

  Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL

  Vincerx Pharma, Inc. today reported that the first patient has been dosed in the Phase 1 trial evaluating VIP943 in patients with relapsed/refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS), and B-cell acute lymphoblastic leukemia (B-cell ALL).

  September 14, 2023

   · 

  7 min read
• Business

  Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to Develop Potential Disease-Modifying Treatment for Gastroparesis

  Aclipse Therapeutics announced today that it has signed an exclusive license agreement with Seoul, South Korea-based Chong Kun Dang Pharmaceutical Corporation (“CKD”).

  September 14, 2023

   · 

  4 min read
• Drug Development

  Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

  Coeptis Therapeutics Holdings, Inc. today provided a safety and patient dosing update from two Phase 1 clinical trials investigating DVX201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with COVID-19 infection.

  September 14, 2023

   · 

  6 min read
• BioMidwest

  OrthoPediatrics Corp. to Participate at the Gilmartin Group Emerging Growth Company Showcase

  OrthoPediatrics Corp. announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Company Showcase on Thursday, September 21, 2023.

  September 14, 2023

   · 

  1 min read
• BetterLife Pharma to Host Investors Update Call on September 18, 2023

  BetterLife Pharma Inc. announces that it will host an investor update Zoom call at 1:30pm PDT (4:30pm EDT) on Monday, September 18, 2023.

  September 14, 2023

   · 

  4 min read
• Pharm Country

  atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

  atai Life Sciences will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference.

  September 14, 2023

   · 

  1 min read
• Drug Development

  Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction

  Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.

  September 14, 2023

   · 

  7 min read